Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

h. lundbeck a/s - nalmefene hydrochloride dihydrat - alkoholrelaterte lidelser - legemidler som brukes i alkoholavhengighet - selincro er indikert for reduksjon av alkoholkonsumet hos voksne pasienter med alkoholavhengighet som har et høyt drikkerisikonivå (se avsnitt 5. 1), uten fysiske tilbakeslagssymptomer, og som ikke krever umiddelbar avgiftning. selincro bør bare forskrives sammen med kontinuerlig psykososial støtte fokusert på behandling tilslutning og redusere alkoholforbruket. selincro bør initieres bare hos pasienter som fortsetter å ha en høy drikke risiko nivå to uker etter den første vurderingen.

Norvēģija - norvēģu - Statens legemiddelverk

sandoz - københavn - fluoksetinhydroklorid - dispergerbar tablett - 20 mg

Norvēģija - norvēģu - Statens legemiddelverk

orion corporation - espoo - fluoksetinhydroklorid - kapsel, hard - 20 mg

Norvēģija - norvēģu - Statens legemiddelverk

vitabalans oy - fluoksetinhydroklorid - tablett, filmdrasjert - 20 mg

Norvēģija - norvēģu - Statens legemiddelverk

eli lilly norge as - fluoksetinhydroklorid - dispergerbar tablett - 20 mg

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.

Norvēģija - norvēģu - Statens legemiddelverk

as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - søvninitiasjon og vedlikeholdssykdommer - psykoleptiske - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.